Items where Author is "Prevost, J."

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of Medical Economics. pp. 109-125. ISSN 1369-6998

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies. Journal of Neurology. pp. 472-485. ISSN 1432-1459 (Electronic) 0340-5354 (Print) 0340-5354 (Linking)

(2023) Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal. pp. 326-332. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Frontiers in Neurology. p. 10. ISSN 1664-2295

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2023) Vascular comorbidities are associated with increased relapse rates in relapsing-remitting MS. Multiple Sclerosis Journal. pp. 84-86. ISSN 1352-4585

(2022) Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study. NEUROLOGY. E2401-E2412. ISSN 0028-3878 1526-632X J9 - NEUROLOGY

(2022) Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study. Neurology. e2401-e2412. ISSN 1526-632X (Electronic) 0028-3878 (Print) 0028-3878 (Linking)

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology. pp. 2321-2334. ISSN 13515101 (ISSN)

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC MEDICAL RESEARCH METHODOLOGY. ISSN 1471-2288 J9 - BMC MED RES METHODOL

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Bmc Medical Research Methodology. p. 14.

(2022) Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Mult Scler. p. 13524585221084577. ISSN 1352-4585

(2021) Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 755-766. ISSN 1352-4585

(2021) Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. E783-E797. ISSN 0028-3878

(2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord. p. 103012. ISSN 2211-0348

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2018) Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 135-137. ISSN 1352-4585

(2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal. pp. 266-276. ISSN 1352-4585

(2017) Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years. Multiple Sclerosis Journal. pp. 361-363. ISSN 1352-4585

(2017) Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 71-73. ISSN 1352-4585

(2017) The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 32-34. ISSN 1352-4585